论文信息 - A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies. - 字舞流文

A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies.

J. Baselga | G. Shapiro | E. Kwak | C. Bedell | G. Edelman | C. Scheffold | A. Laird | L. Nguyen | S. Pandya | J. Rodón | Susan S. Pandya